An innovative clinical study has found that providing pluripotent cells to fetuses affected by spina bifida as part of a surgical repair can be a "significant breakthrough" in treating birth defects.
Trial Details and Safety
The US-based trial examined six unborn babies with the 'open' form of spina bifida. Surgeons applied mother's placental stem cells on the exposed area of the developing neural column as part of the surgical correction.
Significantly, the stem cell application was found to be safe. The study team reported that the therapy did not induce cancerous growths, interfere with wound healing, or impede the resolution of co-occurring hindbrain herniation.
Encouraging Results
Magnetic resonance imaging performed on the newborns showed a complete reversal of hindbrain herniation in each of the babies. This favorable anatomical change is a key indicator for enhanced physical outcomes.
"In the event it allows a greater number of infants capable of walking who previously could not, it may emerge as the new treatment paradigm," said the lead researcher. "These findings are extremely promising and create a pathway toward lots of potential new treatments."
Future Implications and Hope
Independent medical specialists indicated that subsequent studies of these apparent benefits could herald a "different age" in in-utero treatment. The prospect of enhancing neurological damage occurring during fetal development is regarded as a paradigm-shifting aim.
Notably important would be advancements for urogenital and gastrointestinal outcomes, which are typical difficulties for people affected by this condition.
Future Directions
Despite this being a first-in-human effort focused on a handful of cases, its established security and encouraging indicators create a solid basis for expanded clinical research. The addition of cellular treatment with current in-utero repair procedures presents significant potential for improving the prognosis for babies yet to be born with spina bifida.